Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20136057 | 0.84 | NPC1 (0.47) | NPC1RAB9ARECQLRIPK1MEN1 | |
| SCHEMBL8075260 | 0.80 | HCAR3 (0.40) | NPC1RAB9AKMT2A | |
| SCHEMBL3641494 | 0.79 | NPC1 (0.55) | AKT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8079386 | 0.77 | RIPK1 (0.50) | RIPK1MEN1KMT2ALMNAMAPT | |
| SCHEMBL6235763 | 0.77 | RIPK1 (0.50) | RIPK1HTTLMNAMAPTALDH1A1 | |
| SCHEMBL8337464 | 0.77 | GAA (0.43) | RECQLMEN1KMT2AHTTLMNA | |
| SCHEMBL11651848 | 0.75 | NPC1 (0.50) | AKT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13575261 | 0.74 | MEN1 (0.58) | AKT1NPC1RAB9ARECQLRIPK1 | |
| SCHEMBL3085177 | 0.73 | NPC1 (0.48) | NPC1RAB9AMEN1KMT2ACA12 | |
| SCHEMBL10879649 | 0.72 | NPC1 (0.47) | AKT1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | AKT1 235/4885NPC1 1538/4885RAB9A 1229/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | AKT1 191/4885NPC1 922/4885RAB9A 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.